Drawing for EBI EXPONENTIAL BIOTHERAPIES

USPTO serial 87765139

EBI EXPONENTIAL BIOTHERAPIES

Reviewed by CopyMark Law Group

Reg. 6681763Status 700Registered
Filing date
Status date
Registration date
Mar 29, 2022
Examiner
INGRAM, KYLE G
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with EBI EXPONENTIAL BIOTHERAPIES?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

HOPE V. SHOVEIN

HOPE V. SHOVEIN BROOKS KUSHMAN, P.C.1000 TOWN CENTER, 22ND FLOORSOUTHFIELD, MI 48075UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005medicines, namely, medicines for alleviating or treating vasculogenic disease, medicines for alleviating or treating hemodynamic instabilities, medicines for alleviating or treating diabetes, medicines for alleviating or treating of immune system related diseases and disorders; pharmaceutical drugs, namely, pharmaceutical preparations for alleviating or treating vasculogenic disease, pharmaceutical preparations alleviating or treating hemodynamic instabilities, pharmaceutical preparations for alleviating or treating diabetes, pharmaceutical preparations for alleviating or treating of immune system related diseases and disorders; biopharmaceutical drugs, namely, biopharmaceutical preparations for alleviating or treating vasculogenic disease, biopharmaceutical preparations for alleviating or treating hemodynamic instabilities, biopharmaceutical preparations for alleviating or treating diabetes, biopharmaceutical preparations for alleviating or treating of immune system related diseases and disorders; biopharmaceuticals, namely, biopharmaceuticals for alleviating or treating vasculogenic disease, biopharmaceuticals alleviating or treating hemodynamic instabilities, biopharmaceuticals for alleviating or treating diabetes, biopharmaceuticals for alleviating or treating of immune system related diseases and disorders; synthetic peptides for biopharmaceutical purposes and for pharmaceutical purposes, namely, synthetic peptides for alleviating or treating vasculogenic disease, synthetic peptides for alleviating or treating hemodynamic instabilities, synthetic peptides for alleviating or treating diabetes, synthetic peptides for alleviating or treating of immune system related diseases and disorders; synthetic peptidemimetics for biopharmaceutical purposes and for pharmaceutical purposes, namely, sytnthetic peptidomimetics for alleviating or treating vasculogenic disease, synthetic peptidomimetics for alleviating or treating hemodynamic instabilities, synthetic peptidomimetics for alleviating or treating diabetes, synthetic peptidomimetics for alleviating or treating of immune system related diseases and disordersACTIVE—
040custom manufacture of medicines, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals; treatment of biopharmaceutical and pharmaceutical materials being medicines, biopharmaceutical and pharmaceutical compounds, synthetic peptides and synthetic peptidomimetics; processing of medicines, biopharmaceutical and pharmaceutical compounds, synthetic peptides and synthetic peptidomimetics for others; custom manufacture of medical devices for othersACTIVE—
042biopharmaceutical and pharmaceutical research; conducting clinical trials for others in the fields of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; scientific research of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, biopharmaceuticals and pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; development, testing, and inspection of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals; laboratory services relating to medicines, synthetic peptides, synthetic peptidomimetics, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals, namely, research in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; laboratory analysis in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; medical research in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; scientific research for medical purposes in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (R.PR): Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.

DateCodeEventWhat it means
Mar 29, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 11, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 11, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 22, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 7, 2021PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 2, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 2, 2021XAECEXAMINER'S AMENDMENT ENTERED—
Dec 2, 2021GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 2, 2021GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 2, 2021CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 29, 2021ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Nov 9, 2021PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Oct 25, 2021PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Oct 16, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 13, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 13, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 13, 2021ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Oct 12, 2021GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Oct 12, 2021GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Oct 12, 2021CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Oct 1, 2021ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Oct 1, 2021PBSRWITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST—
Oct 1, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 1, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 1, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 1, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 1, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 1, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 1, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 18, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 18, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 17, 2021ALIEASSIGNED TO LIE—
Feb 11, 2021ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Oct 1, 2020GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Oct 1, 2020GNSLLETTER OF SUSPENSION E-MAILED—
Oct 1, 2020CNSLSUSPENSION LETTER WRITTEN—
Sep 11, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 11, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 4, 2020ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Aug 18, 2020GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Aug 18, 2020GNSIINQUIRY TO SUSPENSION E-MAILED—
Aug 18, 2020CNSISUSPENSION INQUIRY WRITTEN—
Aug 4, 2020RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jan 9, 2020GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jan 9, 2020GNSLLETTER OF SUSPENSION E-MAILED—
Jan 9, 2020CNSLSUSPENSION LETTER WRITTEN—
Dec 26, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 26, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 19, 2019ALIEASSIGNED TO LIE—
Dec 16, 2019ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Jun 15, 2019GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Jun 15, 2019GNSIINQUIRY TO SUSPENSION E-MAILED—
Jun 15, 2019CNSISUSPENSION INQUIRY WRITTEN—
Jun 11, 2019RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Nov 20, 2018GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Nov 20, 2018GNSLLETTER OF SUSPENSION E-MAILED—
Nov 20, 2018CNSLSUSPENSION LETTER WRITTEN—
Nov 10, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 9, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 9, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 9, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 9, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 9, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 2, 2018DOCKASSIGNED TO EXAMINER—
Feb 8, 2018AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Feb 7, 2018ALIEASSIGNED TO LIE—
Feb 3, 2018MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Feb 2, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 30, 2018PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jan 25, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance